FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة الأكواد

MAHA Stack

Immune Supportintermediate

82

التعاون

82
Share
البروتيدات

3

متوسط الجرعة اليومية (mcg)

2,600

المستوى

intermediate

تمت الإضافة

May 17, 2026

نظرة عامة

The MAHA Stack — inspired by RFK Jr.''s "Make America Healthy Again" movement and his public advocacy for peptide access — combines three of the most evidence-backed peptides into a foundational health optimization protocol covering healing, immunity, and cognitive function. After HHS Secretary RFK Jr.'s February 2026 signal of intent to reconsider the restricted peptide list — followed by the FDA formally removing 12 peptides from the Category 2 list in April 2026 (removal is not the same as approval, and the peptides remain under PCAC review) — this combination became one of the most searched peptide stacks online. BPC-157 provides systemic healing support — gut mucosal repair, connective tissue regeneration, anti-inflammatory action, and neurotropic effects across the gut-brain axis. Its broad mechanism makes it a foundational health compound rather than a specialized treatment. Thymosin Alpha-1 is an immune modulator originally isolated from the thymus gland. Unlike crude immune "boosters," it precisely calibrates immune function — enhancing the response against pathogens and abnormal cells while reducing excessive inflammatory signaling that drives autoimmune-type conditions. It activates dendritic cells, NK cells, and T-helper cells while modulating cytokine production. Thymosin Alpha-1 has FDA-approved use in some countries for hepatitis and is extensively studied for chronic fatigue, autoimmune conditions, and cancer immunotherapy support. Semax adds the cognitive and neural component — BDNF upregulation, dopaminergic support, and neuroprotection. This is consistent with the MAHA movement''s emphasis on brain health and cognitive function as core components of overall health. Together, this stack represents a "whole-system" approach: healing the body''s physical tissue, calibrating immune function, and supporting the brain — the three systems most impacted by modern inflammatory lifestyles.

بروتوكول الجرعة

BPC-157

Twice per day· subcutaneous

قراءة المزيد عن BPC-157 →

250 mcg

كل جرعة

Thymosin Alpha-1

2x per week· subcutaneous

قراءة المزيد عن Thymosin Alpha-1 →

1,500 mcg

كل جرعة

Semax

Every day· intranasal

قراءة المزيد عن Semax →

600 mcg

كل جرعة

الأهداف والدليل

Whole-system healthImmune calibrationHealingCognitive functionInflammation reduction
درجة الدليل:بيانات بشرية

تحذيرات

  • BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review (July 23, 2026) — not legal to compound yet. Stack peptides individually before combining if new to peptide therapy.

Comments

Sign in to join the discussion

تحذير: هذا الكود مقدم من قبل المجتمع ويهدف لغرض البحث فقط. لا يتحقق Peptide Contacts من سلامة أو فعالية الأكواد المقدمة. استشر محترف صحي مؤهل قبل استخدام أي بروتوكول بروتيني.